Clin Pharmacokinet
-
Meta Analysis
Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.
The aim of this analysis was to develop a population pharmacokinetic model to describe the pharmacokinetics of recombinant human erythropoietin (rHuEPO) in healthy subjects, after intravenous and subcutaneous administration over a wide dose range, and to examine the influence of demographic characteristics and other covariates on the pharmacokinetic parameters of rHuEPO. ⋯ The population pharmacokinetic model developed is suitable to describe the pharmacokinetic behaviour of rHuEPO after intravenous and subcutaneous administration in healthy subjects, over a wide dose range.
-
Meta Analysis
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
To characterise the population pharmacokinetics of trabectedin (ET-743, Yondelis(R)) in cancer patients. ⋯ The integration of trabectedin pharmacokinetic data demonstrated linear elimination, dose-proportionality up to 1.8 mg/m(2) and time-independent pharmacokinetics. The pharmacokinetic impact of dexamethasone and sex covariates is probably limited given the moderate to large interindividual pharmacokinetic variability of trabectedin. The antiemetic and hepatoprotective effects are still a valid rationale to recommend dexamethasone as a supportive treatment for trabectedin.